Company intelligence / Profile preview
EMS
Hortolândia, São Paulo, Brazilems.com.br ↗
- Ownership
- Public · EMSLIMITED
- Employees
- ~4500
- Development stage
- Other
01
Overview
EMS is the largest domestic pharmaceutical company in Brazil and the second largest in Latin America. It operates across all major segments—generics, branded drugs, OTCs—and exports to over 40 countries. The company has pioneered generics since 1999 and maintains an extensive commercial portfolio with strong manufacturing capabilities.
- Therapeutic areas
- ImmunologyEndocrinologyOtherNeurologyInfectious Diseases
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
21 assets20 more assets in the full pipeline.
03
Partnerships
Joint ventures and strategic partnerships with other pharmaceutical companies in over 30 countriesProposed merger with Hypera Pharma as of October 2024—pending completion as of June 2025
04
Financials
- Market cap
- $8.9B
- Total revenue
- $9.4B
- Enterprise value
- $14.8B
Beyond the preview
Go deeper on EMS.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EMS.